India-based Anthem Biosciences is set to finalize its IPO allotment today, July 17, 2025, following robust investor demand. With a ₹3,395 crore offer entirely via offer-for-sale, the IPO saw an overall subscription of 63.86 times. The company’s shares are trading at a ₹144 premium in the grey market, indicating a potential 25.26% listing gain.
India’s pharmaceutical research and development leader Anthem Biosciences is under investor spotlight today, July 17, as it finalizes share allotment for its highly subscribed initial public offering (IPO). The public issue, launched on July 14 and closed on July 16, attracted significant investor interest, signaling continued enthusiasm for the pharmaceutical sector.
The ₹3,395 crore IPO was entirely an offer-for-sale of 5.96 crore equity shares, priced at ₹570 apiece. The company will not receive any fresh capital from this issue, with the offering designed to provide an exit to existing shareholders.
Strong Subscription Across Investor Categories
The IPO was subscribed a remarkable 63.86 times overall. Among key investor segments, Qualified Institutional Buyers (QIBs) led with 182.65 times subscription, followed by Non-Institutional Investors (NIIs) at 42.36 times. The retail investor portion saw 5.64 times oversubscription, reflecting widespread participation.
This overwhelming demand indicates institutional confidence in Anthem Biosciences’ R&D-driven business model, which is focused on contract research and manufacturing for global biopharmaceutical clients. Analysts attribute the response to the company’s robust financials and strong future revenue visibility in the rapidly expanding global life sciences market.
GMP Signals Bullish Sentiment
The grey market premium (GMP) for Anthem Biosciences shares stood at ₹144 today, pushing the estimated listing price to ₹714. This suggests a potential 25.26% premium over the IPO issue price. While grey market trends are unofficial, they are often viewed as a directional indicator of listing expectations.
The equity shares are scheduled to be credited to demat accounts on July 18, with refunds initiated for unsuccessful bidders on the same day. The listing is expected on July 21 on both BSE and NSE.
How to Check Anthem Biosciences IPO Allotment Status
Investors can check their IPO allotment status online through the websites of the stock exchanges and the IPO registrar Kfin Technologies. Here are the methods:
On BSE:
- Go to BSE IPO Allotment Page
- Select ‘Equity’ and choose ‘Anthem Biosciences Limited’
- Enter PAN or Application Number
- Complete the captcha and click ‘Search’
On NSE:
- Visit NSE Allotment Status Page
- Choose ‘Equity and SME IPO bids’ and select the IPO
- Enter PAN and Application Number, then submit
On Kfin Technologies:
- Access Kfin IPO Allotment Portal
- Select ‘Anthem Biosciences Limited’
- Enter either PAN, Application Number, or Demat details
- Submit the Captcha and check status
Market Implications
The strong debut anticipated for Anthem Biosciences mirrors a broader bullish trend in India’s primary market. High oversubscription levels, especially from QIBs, often suggest strong institutional endorsement and long-term conviction. If listing gains materialize, it could bolster sentiment for upcoming IPOs in the pharmaceutical and biotechnology space.
The successful listing of Anthem Biosciences could further validate the increasing role of India in global life sciences R&D outsourcing, a space expected to expand significantly in the next decade. Investors now await the final listing with a keen eye on market conditions and post-listing performance.
